Cargando…

Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study

AIMS: We explored the effect of treatment with ivabradine, a pure heart rate-slowing agent, on recurrent hospitalizations for worsening heart failure (HF) in the SHIFT trial. METHODS AND RESULTS: SHIFT was a double-blind clinical trial in which 6505 patients with moderate-to-severe HF and left ventr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borer, Jeffrey S., Böhm, Michael, Ford, Ian, Komajda, Michel, Tavazzi, Luigi, Sendon, Jose Lopez, Alings, Marco, Lopez-de-Sa, Esteban, Swedberg, Karl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2012
Materias:	Esc Fasttrack
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3498004/ https://www.ncbi.nlm.nih.gov/pubmed/22927555 http://dx.doi.org/10.1093/eurheartj/ehs259

Ejemplares similares

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy
por: Tardif, Jean-Claude, et al.
Publicado: (2011)

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
por: Metra, Marco, et al.
Publicado: (2013)

Effect of Visit‐to‐Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the I (f) Inhibitor Ivabradine Trial (SHIFT) Trial
por: Böhm, Michael, et al.
Publicado: (2016)

Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study(†)
por: Budera, Petr, et al.
Publicado: (2012)

Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry
por: Steg, Ph Gabriel, et al.
Publicado: (2012)

Efficacy of ivabradine in heart failure patients with a high‐risk profile (analysis from the SHIFT trial)
por: Abdin, Amr, et al.
Publicado: (2023)

Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction—a hospital registry-primary care linked cohort (MINAP–GPRD)
por: Boggon, Rachael, et al.
Publicado: (2011)

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
por: Goto, Shinya, et al.
Publicado: (2010)

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
por: James, Stefan, et al.
Publicado: (2010)

Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium(†)
por: Riegger, Julia, et al.
Publicado: (2016)

Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial
por: Zannad, Faiez, et al.
Publicado: (2015)

Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States
por: Borer, Jeffrey S., et al.
Publicado: (2016)

Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.
por: Bouabdallaoui, Nadia, et al.
Publicado: (2019)

Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry
por: Alberts, Mark J., et al.
Publicado: (2009)

The 2021 European Heart Failure Guidelines: The Case for Personalised Therapeutics
por: Shanmugam, Nesan
Publicado: (2022)

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
por: Filippatos, Gerasimos, et al.
Publicado: (2016)

New Trial Evidence on Heart Failure: Highlights from the European Society of Cardiology Congress 2021
por: Ferrannini, Giulia, et al.
Publicado: (2022)

Recent advances in cardio‐oncology: a report from the ‘Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019’
por: Anker, Markus S., et al.
Publicado: (2019)

One year follow-up of the multi-centre European PARTNER transcatheter heart valve study
por: Lefèvre, Thierry, et al.
Publicado: (2011)

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure
por: McMurray, John, et al.
Publicado: (2015)

Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR(CT): outcome and resource impacts study
por: Douglas, Pamela S., et al.
Publicado: (2015)

EuroEco (European Health Economic Trial on Home Monitoring in ICD Patients): a provider perspective in five European countries on costs and net financial impact of follow-up with or without remote monitoring
por: Heidbuchel, Hein, et al.
Publicado: (2015)

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
por: Camm, A. John, et al.
Publicado: (2016)

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2016)

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial
por: Pitt, Bertram, et al.
Publicado: (2011)

Addressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of Ivabradine
por: Pereira-Barretto, Antonio Carlos
Publicado: (2016)

Ivabradine in the treatment of systolic heart failure - A systematic review and meta-analysis
por: Anantha Narayanan, Mahesh, et al.
Publicado: (2017)

Ivabradine tolerability in heart failure
por: Birkhoelzer, Sarah, et al.
Publicado: (2018)

MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy): cardiac resynchronization therapy towards early management of heart failure
por: Breithardt, Günter
Publicado: (2009)

Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2014)

Doppler Echocardiography-Guided Heart Rate Modulation Therapy Using Ivabradine in a Patient with Systolic Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2022)

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure
por: Ponikowski, Piotr, et al.
Publicado: (2014)

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX
por: Gutierrez, J. Antonio, et al.
Publicado: (2016)

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
por: Kastelein, John J.P., et al.
Publicado: (2015)

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2009)

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
por: Steg, Ph. Gabriel, et al.
Publicado: (2011)

The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy
por: Gold, Michael R., et al.
Publicado: (2011)

Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation
por: Matsa, Elena, et al.
Publicado: (2011)

Dyssynchrony by speckle-tracking echocardiography and response to cardiac resynchronization therapy: results of the Speckle Tracking and Resynchronization (STAR) study
por: Tanaka, Hidekazu, et al.
Publicado: (2010)

Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation
por: Hjortnaes, Jesper, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ltdom5cqvff9dd08on5smhqrah